

Evaluating optimal utilisation of technology in type 1 diabetes from a health economic perspective: protocol for a systematic review

Systematic Reviews

2017, 7, 44

DOI: [10.1186/s13643-018-0706-9](https://doi.org/10.1186/s13643-018-0706-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality-of-Life (CSII-QOL) Scale. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 216-221.	2.4	5
2	The Efficacy of Technology in Type 1 Diabetes: A Systematic Review, Network Meta-analysis, and Narrative Synthesis. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 411-421.	2.4	49
3	Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 1967-1975.	4.3	30
4	Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis. <i>Systematic Reviews</i> , 2020, 9, 171.	2.5	20
5	Intelligent automated drug administration and therapy: future of healthcare. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1878-1902.	3.0	19
6	Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics. <i>Farmakoekonomika</i> , 2019, 12, 178-190.	0.4	0